P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy

Agents that block the interaction between the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and its ligands CD112 and CD155 have demonstrated antitumor activity in preclinical tumor models. In the first-in-human study (NCT02964013), the anti-TIGIT humanized monoclonal antibody vibostolimab (MK-7684) showed promising antitumor activity and manageable toxicity in a heavily pretreated population across multiple tumor types, particularly when combined with the PD-1 inhibitor pembrolizumab.